Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The American Society of Hematology (ASH) and the European Hematology Association (EHA) have announced the names of 20 early-career hematologists who will participate in the joint 2017 Translational Research Training in Hematology (TRTH) program. These include two researchers from the MRC WIMM: Dr Lynn Quek and Dr Alice Giustacchini, both in the MRC Molecular Haematology Unit.

american society of hematology logoTRTH is a rigorous year-long training and mentoring experience that helps junior scientists build successful careers in translational hematologic research. Under the guidance of international leaders, participants learn the fundamental principles related to translational research, including developing a hypothesis and testing that hypothesis in the laboratory by applying the scientific method.

TRTH participants include medical, biomedical, and pharmaceutical trainees who are actively employed in a hematology-related research environment as fellows or junior faculty who have completed their fellowship training within the past three years. 

This year’s TRTH program will begin with a week-long course March 11-17 in Italy. It is designed to give participants a more profound understanding of translational research methodology and career development. The course includes didactic and interactive sessions and one-on-one faculty mentoring that focuses on refining participants’ research proposals. TRTH participants will convene again at the 2017 EHA Annual Congress, June 22-25 in Madrid, where they will attend small group mentoring sessions. Finally, participants will present the status of their projects at the conclusion of the program at the 2017 ASH Annual Meeting, December 9-12 in Atlanta.

The TRTH program is made possible by generous support from Celgene, Takeda Oncology, Janssen Pharmaceutica NV, AMGEN (EUROPE) GmbH, Bristol-Myers Squibb, Incyte Corporation, Gilead Sciences, Inc., Astellas Pharma, AstraZeneca, F. Hoffmann-La Roche Ltd.

“I’m pleased that ASH and EHA continue to offer this unique opportunity for junior scientists to learn the principles of translational research. This experience will give them the knowledge and support to turn their talents into discoveries that will count for patients,” said ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston. “As a mentor myself, I am proud that ASH supports programs that train and support the next generation of scientists.”

The American Society of Hematology (ASH) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood.

Similar stories

Mechanism behind repair of cancer-inducing mutations discovered

New Nature paper uncovers the precise mechanism behind how the BRCA1 protein detects and engages with DNA breaks in the genome, helping to prevent the development of breast and ovarian cancers.

DNA breakthrough could help identify why some people are more affected by Covid-19

Scientists from the MRC Weatherall Institute of Molecular Medicine have developed a method that allows them to see, with far greater accuracy, how DNA forms large scale structures within a cell nucleus.

New clinical trial for patients affected by blood cancer

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Immune cells imperfect at distinguishing friend from foe

When it comes to distinguishing a healthy cell from an infected one that needs to be destroyed, the immune system’s killer T cells sometimes make mistakes. This discovery, described today in the journal eLife, upends a long-held belief among scientists that T cells were nearly perfect at discriminating friend from foe. The results may point to new ways to treat autoimmune diseases that cause the immune system to attack the body, or lead to improvements in cutting-edge cancer treatments.

New funding for early diagnosis research using platelets

Dr Bethan Psaila and her team will investigate the potential of circulating blood platelets for early detection of a range of cancer types.